CD274 and neoplasm: ICB therapy enhances anti-tumor immunity by blocking intrinsic immune factors that are down-regulated, such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death receptor 1 (PD-1), or its ligand, programmed cell death ligand 1 (PD-L1) [3].